ResMed Inc.
RMD · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 3.58B | 2.02B | 1.00B | 779.44M | 5.34 |
| 2023 FY | 4.22B | 2.36B | 1.13B | 897.56M | 6.12 |
| 2024 FY | 4.69B | 2.66B | 1.32B | 1.02B | 6.94 |
| 2025 FY | 5.15B | 3.05B | 1.69B | 1.40B | 9.55 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 5.10B | 1.74B | 273.71M | 917.55M | 3.36B |
| 2023 FY | 6.75B | 2.62B | 227.89M | 1.58B | 4.13B |
| 2024 FY | 6.87B | 2.01B | 238.36M | 873.94M | 4.86B |
| 2025 FY | 8.17B | 2.21B | 1.21B | 851.81M | 5.97B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 351.15M | -156.04M | 195.11M | -245.34M | -21.57M |
| 2023 FY | 693.30M | -134.00M | 559.30M | -258.28M | -45.82M |
| 2024 FY | 1.40B | -114.86M | 1.29B | -282.32M | 10.47M |
| 2025 FY | 1.75B | -89.87M | 1.66B | -310.88M | 971.09M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 30.62B | 31.26B | — | — | — |
| 2023 FY | 32.07B | 33.42B | — | — | — |
| 2024 FY | 27.48B | 28.12B | — | — | — |
| 2025 FY | 37.85B | 37.50B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2027-06-30 | — | — | — | — | — |
| 2028-06-30 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q4 | 1.35B | 820.07M | 454.54M | 379.71M | 2.59 |
| 2026 Q1 | 1.34B | 820.82M | 446.54M | 348.54M | 2.38 |
| 2026 Q2 | 1.42B | 884.66M | 497.60M | 392.59M | 2.69 |
| 2026 Q3 | 1.43B | 890.98M | 499.81M | 398.73M | 2.72 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q4 | 8.17B | 2.21B | 1.21B | 851.81M | 5.97B |
| 2026 Q1 | 8.31B | 2.19B | 1.38B | 846.35M | 6.12B |
| 2026 Q2 | 8.50B | 2.18B | 1.42B | 1.00B | 6.32B |
| 2026 Q3 | 8.78B | 2.29B | 1.66B | 843.17M | 6.49B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q4 | 538.77M | -30.59M | 508.18M | -77.59M | 276.74M |
| 2026 Q1 | 457.32M | -42.97M | 414.36M | -87.75M | 174.40M |
| 2026 Q2 | 339.75M | -34.56M | 305.19M | -87.58M | 33.22M |
| 2026 Q3 | 554.13M | -33.65M | 520.48M | -87.24M | 243.44M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q4 | 37.79B | 37.43B | — | — | — |
| 2026 Q1 | 40.09B | 39.56B | — | — | — |
| 2026 Q2 | 35.28B | 34.87B | — | — | — |
| 2026 Q3 | 32.88B | 32.06B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |